Likewise, abnormal expression of cyclin A2 is associated with chromosomal instability and tumor proliferation, while inhibition leads to decreased tumor growth. Therefore, CDK2 and its cyclin binding partners represent possible therapeutic targets for new cancer therapeutics. Pre-clinical models have shown preliminary success in limiting tumor growth, and have also been observed to reduce side effects of current chemotherapy drugs.
Abnormal expression of cyclin A2 is linked to chromosomal instability and tumor proliferation, while inhibition results in reduced tumor growth. Consequently, CDK2 and its cyclin binding partners could be potential therapeutic targets for new cancer treatments. Preclinical studies have indicated that these targets can limit tumor growth and reduce side effects from current chemotherapy drugs.